Marketing approval of mogamulizumab: A triumph for glyco-engineering
Therapeutic properties of antibodies strongly depend on the composition of their glycans. Most of the currently approved antibodies are produced in mammalian cell lines, which yield mixtures of different glycoforms that are close to those of humans, but not fully identical. Glyco-engineering is bein...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Landes Bioscience
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499336/ |